PremiumThe FlyUnusually active option classes on open February 18th Crispr Therapeutics price target lowered to $82 from $89 at Citi Airbnb, Moderna report Q4 results: Morning Buzz PremiumThe FlyCrispr Therapeutics price target lowered to $49 from $53 at Stifel Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb Promising Growth Prospects for Crispr Therapeutics AG: Buy Rating Affirmed by Kostas Biliouris PremiumThe FlyCrispr Therapeutics price target lowered to $48 from $53 at RBC Capital Crispr Therapeutics price target raised to $120 from $100 at Truist Crispr Therapeutics AG: Strong Financial Position and Strategic Advancements Justify Buy Rating 
